Cardiff Oncology vs Onconetix
CRDF and ONCO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRDF and ONCO compare
Cardiff Oncology is the larger company, worth 5.2 times as much as Onconetix ($65.3M against $12.4M).
Cardiff Oncology grew revenue faster over the last twelve months (−7.0% versus −51.3% for Onconetix).
Onconetix keeps more of each dollar of sales as profit, with a net margin of −1579% compared with −7884% at Cardiff Oncology.
Cardiff Oncology scores higher on the StockData Score (7 against 3 for Onconetix), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRDF | ONCO |
|---|---|---|
| Size and price | ||
| Market cap | $65.3M | $12.4M |
| Share price | $0.839 | $3.15 |
| Change, 1 year | −59.3% | −99.7% |
| Change, 5 years | −85.0% | −100.0% |
| Beta (5Y) | 1.58 | 4.81 |
| Employees | 31 | 12 |
| StockData Score | ||
| Total score | 7 (better) | 3 |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 | 1 |
| Performance score | 1 (better) | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 128× | 19.3× (better) |
| P/B | 2.5× | 0.9× (better) |
| Growth | ||
| Revenue growth (TTM) | −7.0% (better) | −51.3% |
| Revenue growth, 5Y average | 10.1% | – |
| Profitability | ||
| Gross margin | – | 80.4% |
| Operating margin | −8320% | −2525% (better) |
| Net margin | −7884% | −1579% (better) |
| Return on equity | −94.1% (better) | −105% |
| Return on invested capital | – | −196% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −52.4× |
| Current ratio | 3.30 (better) | 2.21 |
| Altman Z-score | −16.24 | −12.24 (better) |
| Piotroski F-score | 1 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 24.2% | 1.7% |
| Held by insiders | 4.9% | 40.3% |
| Insider net buying, 12 months | $1.1M (better) | $8.4K |
| Short interest, % of float | 16.6% | 40.6% |
Go deeper
- CRDF stock overview
- CRDF income statement
- CRDF valuation and score
- ONCO stock overview
- ONCO income statement
- ONCO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.